Skip to content
ppharmaranks
Menu

SGLT2 inhibitors compared

Compare all 2 SGLT2 inhibitors side by side, used for conditions such as diabetes mellitus, type 2. SGLT2 inhibitors are the Sodium-Glucose Cotransporter 2 Inhibitor class. They share one FDA-defined mechanism but differ in approved uses, prescription status, brand-vs-generic options, price, and FDA recall-safety record — which our independent rating scores.

Full ranking · 2 drugs

  1. 1

    invokana

    Canagliflozin

    70/100
  2. 2

    farxiga

    Dapagliflozin

    New

Frequently asked questions

What is the Sodium-Glucose Cotransporter 2 Inhibitor drug class?

Sodium-Glucose Cotransporter 2 Inhibitor is an FDA Established Pharmacologic Class (EPC) — a group of drugs that share a mechanism of action. pharmaranks lists 2 Sodium-Glucose Cotransporter 2 Inhibitor products, each independently rated.

Are all Sodium-Glucose Cotransporter 2 Inhibitor drugs the same?

No. Sodium-Glucose Cotransporter 2 Inhibitor drugs share the same core mechanism — that is why they sit in one FDA class — but they differ in their approved uses, available forms, whether they are prescription or over-the-counter, brand-vs-generic options and price, and their FDA recall-safety record.

Is "SGLT2 inhibitors" the same as the Sodium-Glucose Cotransporter 2 Inhibitor class?

Yes — "SGLT2 inhibitors" is the everyday name for the Sodium-Glucose Cotransporter 2 Inhibitor drug class. This page compares the 2 SGLT2 inhibitors pharmaranks rates, with our independent FDA recall-safety score for each.

What conditions do Sodium-Glucose Cotransporter 2 Inhibitor drugs treat?

Per NIH RxClass drug-classification data, Sodium-Glucose Cotransporter 2 Inhibitor drugs are used for conditions including diabetes mellitus, type 2.

Sources: the Sodium-Glucose Cotransporter 2 Inhibitor class definition and its member drugs come from the U.S. NLM RxClass (Established Pharmacologic Class). Ratings are pharmaranks’ independent FDA recall-safety analysis.